Dynamics of immunological reactivity indices in patients with laryngal papillomatosis at different periods after complex treatment with antivirus qudrivalent vaccine "Gardasil"





laryngeal papillomatosis, immunological reactivity, antirelapse therapy, antiviral quadrivalent vaccine


The aim of the study is to determine di­sorders of immune homeostasis in patients with laryngeal papillomatosis at different periods after complex treatment with the inclusion of the “Gardasil” quadrivalent vaccine in the adjuvant therapy. Studies of the immunity state were conducted in 26 patients with laryngeal papillomatosis (LP) before, 2-12 and 13-29 months after complex treatment, consisting of surgical removal of papillomas and anti-relapse therapy, including inhalation of Laferobion, taking a vitamin-mineral complex and a course of vaccination with antiviral “Gardasil” quadrivalent vaccine according to which the second and third injections were administered in 2 and 6 months after the first. Significant disorders of cellular and humoral immunity indices in patients with LP were revealed in the form of multidirectional changes in the functional activity of natural killer cells, a decrease in the total number of T lymphocytes, mainly due to CD4 + subpopulation, increase in circulating immune complexes level in blood serum and concentration of secretory IgA in the secretion of the oropharynx. Disbalance in the patient’s cytokine system resulted in increased γ-IFN and TNF-α serum levels, an increase in spontaneous production of interferon and inhibition of stimulated production of λ - and γ-interferon by blood cells in vitro. Complex treatment with the use of the “Gardasil” quadrivalent antiviral vaccine in the postoperative period contributed to the normalization of most immunological reactivity indices that were altered in patients. The results indicate the prospects of using the antiviral vaccine as part of adjuvant antirelapse therapy after surgical treatment of LP patients and indicate the advisability of long-term clinical and immunological monitoring at different periods after vaccination.

Author Biographies

D. I. Zabolotny

SI“ Institute of Otolaryngology namedafter Prof. O.S. Kolomiychenko of NAMS of Ukraine”
Zoologichnastr, 3, Kyiv, 03057, Ukraine

M. B. Sambur

SI“ Institute of Otolaryngology namedafter Prof. O.S. Kolomiychenko of NAMS of Ukraine”
Zoologichnastr, 3, Kyiv, 03057, Ukraine

T. D. Savchenko

SI“ Institute of Otolaryngology namedafter Prof. O.S. Kolomiychenko of NAMS of Ukraine”
Zoologichnastr, 3, Kyiv, 03057, Ukraine

L. D. Krіvokhatskaуа

SI“ Institute of Otolaryngology namedafter Prof. O.S. Kolomiychenko of NAMS of Ukraine”
Zoologichnastr, 3, Kyiv, 03057, Ukraine

T. A. Zayets

SI“ Institute of Otolaryngology namedafter Prof. O.S. Kolomiychenko of NAMS of Ukraine”
Zoologichnastr, 3, Kyiv, 03057, Ukraine

M. D. Tymchenko

SI“ Institute of Otolaryngology namedafter Prof. O.S. Kolomiychenko of NAMS of Ukraine”
Zoologichnastr, 3, Kyiv, 03057, Ukraine


Antomonov MYu. [Mathematical processing and analysis of biomedical data. 2nd edition]. Kyiv: MIC "Medinform"; 2017. p. 579. Russian.

Belozerov ES, Makarova TA. [Precipitation me­thod of immune complexes investigation in patients with viral hepatitis B]. Lab. delo. 1982;(12):741-43. Russian.

Dzyublyk IV, Trokhimenko OP, Krivokhats­ka LD, Kovalyuk OV. [Human interferon status in viral infections]. Method. Recommendations. Kyiv Medical Academy after the diploma education named after PL Shupyk of the Ministry of Health of Ukraine; 2002. p. 12. Ukrainian.

Zabolotny DI, Dzyublyk IV, Kovalyuk OV, Sav­chenko TD, Klochkov EI, Artemchuk GP. [ Clinical and virological features in patients with laryngeal papillo­matosis]. Zhurn. Vushnih, Nosovih and Gorlov. Hvorob. 2014;(3):59-64. Ukrainian.

Melnikov OF, Zayets TA. [Comparison of ra­dioisotope and spektrofotometric method for determining cell cytotoxicity]. Lab. diagnostika. 1998;(1):43-45. Russian.

Novikov DK, Novikov PD. [Method of determi­ning the T- and B-lymphocyte based on monoclonal antibody]. Immunologiya. 2000;(2):31-33. Russian.

Sambur MB, Zabolotny DI, Savchenko TD, Kri­vokhatskaya LD, Timchenko MD, Zayats TA. [The effectiveness of antirelapse treatment of recurrent laryngeal papillomatosis with the use of the vaccine "Gardasil" in the long term] Zhurn. Vushnih Nosovih and Gorlov. Hvorob. 2015;(5);60-61. Ukrainian.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Stern-berg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kur-man R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirusvaccine in women aged 16-26 years: a rando-mised, double-blind trial. Lancet. 2017;390(10108):2143-59. doi: https://doi.org/10.1016/S0140-6736(17)31821-4

Tjon Pian Gi RE, San Giorgi MR, Pawlita M, Michel A, van Hemel BM, Schuuring EM, van den Heuvel ER, van der Laan BF, Dikkers FG. Immuno-logical response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. Eur. Arch. Oto-rhinolaryngol. 2016;273(10):3231-6. doi: https://doi.org/10.1007/s00405-016-4085-3

Larson DA, Derkay CS. Epidemiology of recur­rent respiratory papillomatosis. APMIS. 2010;118(6-7):450-4. doi: https://doi.org/10.1111/j.1600-0463.2010.02617.x

Pan XF, Wang J, Xiao Y. Research status of hu-man papillomavirus vaccine for prevention and treatment of respiratory papillomatosis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019;33(2):189-92. doi: https://doi.org/10.13201/j.issn.1001-1781.2019.02.025

Toh ZQ, Kosasih J, Russell FM, Garland SM, Mulholland EK, Licciardi PV. Recombinant human papil-lomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist. 2019 Jul 4;12:1951-67. doi: https://doi.org/10.2147/IDR.S178381

Bonagura VR, Hatam LJ, Rosenthal DW, DeVoti JA, Lam F, Steinberg BM, Abramson AL. Recur­rent Respiratory Papillomatosis. A complex defect in res­ponsiveness to human papillomavavirus-6 and -11. APMIS. 2010;118(6-7):455-70. doi: https://doi.org/10.1111/j.1600-0463.2010.02617.x

Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, Souza CA, Marchiori E. Recurrent respiratory papillomatosis: A state-of-the-art review. Respir. Med. 2017;126:116-21. doi: https://doi.org/10.1016/j.rmed.2017.03.030

Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018;36(32Pt A):4768-73. doi: https://doi.org/10.1016/j.vaccine.2017.12.079

Slifka MK, Amanna IJ. Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses. Front. Immunol. 2019;10:956-9. doi: https://doi.org/10.3389/fimmu.2019.00956

Sullivan C, Curtis S, Mouzakes J. Therapeutic use of the HPV vaccine in Recurrent Respiratory Papillomatosis: A case report. Int. J. Pediatr. Otorhinolaringol. 2017;93:103-6. doi: https://doi.org/10.1016/j.ijporl.2016.12.035



How to Cite

Zabolotny DI, Sambur MB, Savchenko TD, Krіvokhatskaуа LD, Zayets TA, Tymchenko MD. Dynamics of immunological reactivity indices in patients with laryngal papillomatosis at different periods after complex treatment with antivirus qudrivalent vaccine "Gardasil". Med. perspekt. [Internet]. 2020Oct.5 [cited 2024Jul.15];25(3):87-95. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/214820